【摘要】 原发性免疫性血小板减少症（ITP）是一种常见的出血性疾病。目前，血小板受体激动剂代表药物——艾曲波帕临床应用日益广泛，尽管在一定程度上改善了ITP患者的预后和生存质量，但药物依赖、耐药、费用昂贵等相关问题逐渐凸显，从而寻求中药治疗以减撤促稳。中医“调肝扶脾法”介入艾曲波帕治疗能够起到协同增效作用，促进病情稳定，值得总结关注。文章分享3则典型病案，以期进一步提升临床疗效。更多还原

【Abstract】 Primary immune thrombocytopenia(ITP) is a common hemorrhagic disease. At present,the representative drug of platelet receptor agonist-eltrombopag has become more and more widely used in clinical practice. Although the prognosis and quality of life of ITP patients have been improved to a certain extent,the problems related to drug dependence,drug resistance and economic cost have gradually become prominent,so as to seek traditional Chinese medicine(TCM) to reduce withdrawal and promote stability. “Regulating the liver and strengthening the spleen ”intervention in the syndrome differentiation and treatment of eltrombopag can help increase efficiency and promote the stability of the disease. This phenomenon is worthy of summary and attention. Three typical cases were shared to further improve the clinical efficacy.更多还原